---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-095741"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:46:27.970561+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q4 product revenue $742K vs $69K YoY; net loss $3.1M; FDA clears OneRF Ablation System

## Summary
- Product revenue $742K (Q4) vs $69K YoY; full year $1.952M vs $171K.
- Net loss $3.1M (Q4) vs $1.4M; full year $11.9M vs $10.0M.
- Received FDA 510(k) clearance for OneRF Ablation System in Dec 2023; commercial launch expected H1 2024.
- Cash $5.3M as of Sep 30, 2023, down from $11.1M; raised $5.2M net in public offering and $2.5M via ATM at $1.77/share.
- Zimmer Biomet expanding Evo sEEG launch; device sales ramp expected quarter by quarter.

## SEC filing metadata
- accession: 0001213900-23-095741
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390023095741/0001213900-23-095741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390023095741/ea189916-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-095741
- JSON: https://secwatch.observer/filing/0001213900-23-095741.json
- Plain text: https://secwatch.observer/filing/0001213900-23-095741.txt

## Key facts
- Earnings Releases
  NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal fourth quarter and full fiscal year ended September 30, 2023 results: revenue Product revenue of $742,000 in Q4 2023, net income Net loss was $3.1 million for the fourth quarter of fiscal 2023.
  - Period: fiscal fourth quarter and full fiscal year ended September 30, 2023
  - Revenue: Product revenue of $742,000 in Q4 2023
  - Net income: Net loss was $3.1 million for the fourth quarter of fiscal 2023
  - Result: reported results
  source text: On December 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390023095741/0001213900-23-095741-index.htm
- Earnings Releases
  NEUROONE MEDICAL TECHNOLOGIES Corp reported full fiscal year ended September 30, 2023 results: revenue Product revenue of $1,952,000 for FY 2023, net income Net loss was $11.9 million for the full year fiscal 2023.
  - Period: full fiscal year ended September 30, 2023
  - Revenue: Product revenue of $1,952,000 for FY 2023
  - Net income: Net loss was $11.9 million for the full year fiscal 2023
  - Result: reported results
  source text: today announces its operating results for the fiscal fourth quarter and full fiscal year ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390023095741/0001213900-23-095741-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.